Revlimid

The Food and Drug Administration announced Monday it would publish correspondence with drug manufacturers accused of abusing agency standards to foil generic competitors. Height Capital Markets considers the public censuring indicative of a broader federal strategy to pressure industry change....

Biopharma Celgene Corporation (NASDAQ: CELG) reported first-quarter earnings, lowered its 2018 full-year EPS guidance and raised its sales guidance for the year before the open Friday.  What Happened Total net product sales of $3.53 billion in Q1 were 20 percent higher from the same...

Celgene Corporation (NASDAQ: CELG) stock tanked Thursday, dropping close to 20 percent on roughly nine times its average volume. The downside was orchestrated by weaker-than-expected third-quarter revenues announced by the company Thursday. At the time of writing, shares of Celgene were down...

Celgene Corporation (NASDAQ: CELG) has gained about 15 percent from its mid-August lows. Against this backdrop of share price appreciation, Morgan Stanley said in a note Thursday that the consensus expectations underappreciate the potential for generic Revlimid as early as April 2020 and the...

Argus' David Toung downgraded shares of Celgene Corporation (NASDAQ: CELG) from Buy to Hold after fully digesting the company's first-quarter earnings report. Stay Critical, Investors According to Toung, investors have reason to be "concerned" over the company's revenue concentration from Revlimid...

Leerink's Global Healthcare Conference kicked off Wednesday and will continue through Thursday. Here is a summary of what Leerink's analysts are saying about some of the notable companies who presented at on Wednesday. Universal Health Services Universal Health Services, Inc. (NYSE: UHS)'s chief...

Orphan drugs, drugs intended to prevent, diagnose or treat rare diseases/disorders, are huge sellers for the pharmaceutical industry. NPR, citing data from EvaluatePharma, noted that seven of the 10 best-selling drugs in the United States throughout 2015 were given an orphan drug status. The main...

The American Society of Hematology (ASH) held its annual December meeting in San Diego, where some of the biggest biotech companies announced clinical trial results, new drug updates and future initiatives. In separate reports, Cantor Fitzgerald analysts mentioned their takes on the announcements...

Amgen, Inc. (NASDAQ: AMGN) announced that the Phase 3 CLARION trial for Kyprolis in first-line multiple myeloma (MM) did not meet the primary endpoint. Goldman Sachs’ Terence Flynn maintains a Buy rating on the company, while lowering the price target from $206 to $198. Disappointing Data...

Shares of Celgene Corporation (NASDAQ: CELG) were trading higher by 0.43 percent at $108.11 after the company reported its second-quarter results. Celgene said it earned $1.44 per share in the second quarter on revenue of $2.74 billion. Wall Street analysts were expecting the company to earn $1.39...

Canaccord Genuity reiterated its Buy rating and $156 price target on Celgene Corporation (NASDAQ: CELG). In the report published Friday, the analysts stated their positive outlook for the near-term data readouts for Revlimid from REMARC and Otezla in Atopic Dermatitis. Additionally, they expect...

Shares of Celgene Corporation(NASDAQ: CELG) on Tuesday plunged to a mid-day low of $121.41. The move came in response to a Bloomberg report the U.S. Patent & Trademark Organization may soon be reviewing a patent challenge brought on by Kyle Bass's Coalition for Affordable Drugs related to...